Louvain la Neuve, Belgium, 1st October 2019 / Sciad Newswire / N-SIDE, provider of innovative software and strategic consulting services, announced that AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials. Within the scope of this agreement, AstraZeneca will use specifically the N-SIDE Supply and Dashboard Apps in order to design, plan and monitor their clinical trial supply chain.
News
Cambridge, UK, 30 September 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes.
Today, Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board. Clare Terlouw, Head of Corporate Development at Syncona Investment Management Limited and Jon Green, Chair of One Nucleus, will be joining the SBC Board on 1st October 2019.
Cambridge, UK; September 27, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will present a poster today that details an expanding body of evidence for the dual mechanism-of-action of the company’s anti-ICOS program, KY1044. The poster will be presented at the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON), being held at the Espace Grande Arche in Paris September 25-28, 2019.
AMSBIO has introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Royston, UK – Sept. 24, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined UK Medicines Discovery Catapult’s Discovery Services Platform, partnering with other best-in-class service providers to help improve preclinical drug discovery success rates.
Harpenden, UK, 24 September 2019: St George Street Capital (SGSC), a UK registered charity, has signed a license agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
Aston Particle Technologies (APT) has significantly expanded its in-house R&D capabilities by investing in two benchtop systems – designed by Ely-based GB Innomech (Innomech) – to prepare small quantities of blended pharmaceutical powders for use in its formulation development projects for pharmaceutical companies.
Global Regulatory Services (GRS) spins out new Irish Consultancy, Med-Di-Dia, to focus on EU MedTech
GRS spins out new Irish Consultancy, Med-Di-Dia (www.med-di-dia.com), to focus on EU MedTech regulations and quality compliance requirements. The official launch was held in Galway on Monday 16th September 2019. We were delighted to welcome the Mayor of Galway, Councillor Mike Cubbard, who started our celebrations with a thoughtful and supportive speech. And talking about ‘support’, we’ve had such a warm welcome by the Galway Technology Centre (where the new office is), Galway City and Ireland as a whole. Everyone has been so helpful.
Cambridge 23September 2019:As the second cohort of Accelerate@Babraham start up competition winners begin their five-month programme, the Babraham Research Campus has confirmed a further injection of financial and mentoring support for the initiative from new sponsors LifeArc. The additional funding will bolster the ability of the Babraham Research Campus to drive innovation in early science within the Cambridge life science cluster.